Taking control of even the generic pharma market will bring tremendous advantages to human capital, national security, and contributions to health care sector.
Time for a change not only in control of natural resources, but resources provided to well-being of all.
BEMA
http://www.scidev.net/global/medicine/analysis-blog/private-sector-india-generic-drug-wars.html
"The African market, expected to be worth US$30 billion by 2016,"
PHARMACEUTICALS
Threats to the Pharmacy of
the Developing World
Africans who depend on drugs produced on the cheap in India could pay the steepest price if proposed changes to Indian patent law are pushed through, warns Maha Rafi Atal, a PhD candidate at the University of Cambridge, United Kingdom.
Indian companies ran afoul of Big Pharma in the 1970s when they began to only recognize patents for drug-making processes, rather than products. This opened the door for Indian companies to alter processes and “reverse engineer” medications cheaply, which they began exporting to poor countries. For example, they provide about 80% of the antiretrovirals used to treat HIV/AIDS in Africa.
Now, under US pressure, India could change its laws—and that arrangement could unravel. As Aaron Motsoaledi, South Africa's health minister, said, “We regard India as the pharmacy of the developing world … They were our heroes, and if they change their laws now, we will be in big trouble in Sub-Saharan Africa.”
SciDevNet
Time for a change not only in control of natural resources, but resources provided to well-being of all.
BEMA
http://www.scidev.net/global/medicine/analysis-blog/private-sector-india-generic-drug-wars.html
"The African market, expected to be worth US$30 billion by 2016,"
Bringing science and development together through original news and analysis
PHARMACEUTICALS
Threats to the Pharmacy of
the Developing WorldAfricans who depend on drugs produced on the cheap in India could pay the steepest price if proposed changes to Indian patent law are pushed through, warns Maha Rafi Atal, a PhD candidate at the University of Cambridge, United Kingdom.
Indian companies ran afoul of Big Pharma in the 1970s when they began to only recognize patents for drug-making processes, rather than products. This opened the door for Indian companies to alter processes and “reverse engineer” medications cheaply, which they began exporting to poor countries. For example, they provide about 80% of the antiretrovirals used to treat HIV/AIDS in Africa.
Now, under US pressure, India could change its laws—and that arrangement could unravel. As Aaron Motsoaledi, South Africa's health minister, said, “We regard India as the pharmacy of the developing world … They were our heroes, and if they change their laws now, we will be in big trouble in Sub-Saharan Africa.”
SciDevNet
